Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30255085 | 1.00 | PRMT5 (0.79) | PRMT5WDR77 | |
| SCHEMBL15824947 | 1.00 | PRMT5 (0.79) | PRMT5WDR77 | |
| SCHEMBL15830402 | 0.91 | PRMT5 (0.69) | PRMT5WDR77 | |
| SCHEMBL16217425 | 0.90 | PRMT5 (0.79) | PRMT5WDR77 | |
| SCHEMBL17377083 | 0.89 | PRMT5 (0.64) | PRMT5WDR77 | |
| SCHEMBL17377192 | 0.89 | PRMT5 (0.64) | PRMT5WDR77 | |
| SCHEMBL17377000 | 0.89 | PRMT5 (0.62) | PRMT5WDR77 | |
| SCHEMBL17377262 | 0.89 | PRMT5 (0.62) | PRMT5WDR77 | |
| SCHEMBL17377065 | 0.89 | PRMT5 (0.62) | PRMT5WDR77 | |
| SCHEMBL17377008 | 0.89 | PRMT5 (0.62) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522584-B2 | 3,4-dihydroisoquinoline compound and use thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2026-01-13 | — | — | US | disclosed |
| US-20250051307-A1 | SALT OF 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO.,LTD (CN) | 2025-02-13 | — | — | US | disclosed |
| EP-4446317-A1 | SALT OF 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230183206-A1 | 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230183206-A1 | 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| WO-2023104107-A1 | SALT OF 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-20230183206-A1 | 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| EP-4155301-A1 | 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2023-03-29 | — | — | EP | disclosed |
| US-20150252031-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-09-10 | — | — | US | disclosed |
| US-20150252031-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-09-10 | — | — | US | disclosed |
| US-8993555-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993555-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993555-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140329794-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329794-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329794-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2014100719-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100719-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252031-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 48/4885 |
| US-20230183206-A1 | 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | PRMT5, PRMT3, PRMT1 | PRMT5 1/4885WDR77 71/4885 |
| US-20140329794-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 48/4885 |
| US-20250051307-A1 | SALT OF 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | SLC26A3, SLC38A7, SLC10A1 | PRMT5 2567/4885WDR77 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.